Integrating Tissue and Liquid Biopsy for In-Depth Precision Oncology Insights

Type: On-Demand Webinar
Location: Global
Areas of Interest: Liquid Biopsy, Oncology, Solid Tumors

Precision oncology depends on biomarker testing to uncover the molecular drivers of cancer. However, no single assay captures the full picture of tumor complexity. Tissue and liquid biopsy each offer distinct, complementary windows into solid tumor analysis, and combining them delivers a more comprehensive molecular view to guide decision-making.

This webinar will examine how tissue and liquid biopsy data can be unified within a decentralized workflow using the SOPHiA DDM™ Platform in combination with end-to-end Memorial Sloan Kettering Cancer Center (MSK) solutions, enabling comprehensive genomic profiling without compromising data locality or turnaround time.

Key topics will include:

The rationale for combining tissue and liquid biopsy analysis to strengthen oncology research, including how each modality addresses the limitations of the other.
Real-world implementation of comprehensive genomic profiling solutions at Tata Memorial Hospital, India, illustrating tissue and liquid biopsy workflows in practice.
Recent enhancements to MSK powered with SOPHiA DDM™ solutions, expanding capabilities for advanced solid tumor analysis, including tumor content estimates and broader biomarker detection.

Speakers

Dr. Omshree Shetty, Ph.D., Scientific Officer, Assistant Professor, Molecular Pathology Laboratory, Tata Memorial Hospital
Lina Li, Director of Product Marketing for Solid Tumors, SOPHiA GENETICS

Watch Webinar

Comments

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Company(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services